Nuvelo, Inc. (Nasdaq: NUVO) announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or radiation-induced oral mucositis models. The data were presented in a poster session yesterday at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

More: continued here

This entry was posted on Thursday, April 17th, 2008 at 12:04 pm and is filed under GastroIntestinal / Gastroentorology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.